BRIEF-Teva reports FDA acceptance of resubmitted NDA for SD-809
October 20, 2016 at 09:12 AM EDT
* Teva announces FDA acceptance of resubmitted new drug application for SD-809 for treatment of Chorea associated with Huntington disease
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.